Guidance document on classification of veterinary drugs and livestock feeds

Notice

April 12, 2017

Guidance Document on Classification of Veterinary Drugs and Animals Feeds – updated version

Health Canada's Veterinary Drugs Directorate (VDD) and the Canadian Food Inspection Agency's Animal Feed Division (AFD) are pleased to announce the release of the final versions of two appendices included in the Guidance Document on Classification of Veterinary Drugs and Livestock Feeds.

The additional appendices are intended to provide assistance to sponsors, manufacturers or consultants in determining the appropriate regulatory oversight for a product destined for use in livestock species. Appendix D provides direction for product classification on stress-related indications and Appendix E-1 will aid in the classification of Mycotoxin Detoxifying Agents (MDAs), including mycotoxin binders. The Classification Information Template cannot be published online as a fillable form, but it is available for classification requests as an electronic document. It can be requested via an email to classification-vet@hc-sc.gc.ca.

Feedback from the online consultation in November 2015 was considered in the finalization of these appendices. Comments from stakeholders were generally supportive of the content.

Questions or concerns regarding this guidance document should be directed to the Veterinary Drugs Directorate.

Published by authority of the Minister of Health and the Minister of Agriculture and Agri-Food

Veterinary Drugs Directorate
Health Products and Food Branch
Health Canada
and
Animal Feed Division
Animal Health Directorate
Canadian Food Inspection Agency

Foreword

Guidance documents are meant to provide assistance on how to comply with the policies and governing statutes and regulations. They also serve to provide review and compliance guidance to government employees, thereby assuring that mandates are implemented in a fair, consistent and effective manner.

Guidance documents are administrative instruments not having force of law and, as such, allow for flexibility in approach. Alternate approaches to the principles and practices described in this document may be acceptable provided they are supported by adequate scientific justification. Alternate approaches should be discussed in advance with the relevant program area to ensure that applicable statutory or regulatory requirements have been met.

As a corollary to the above, it is equally important to note that Health Canada and the Canadian Food Inspection Agency (CFIA) reserve the right to request information or material, or define conditions not specifically described in this guidance, in order to allow for the adequate assessment of the safety, efficacy or quality of a product. Both Health Canada and the CFIA are committed to making sure that such requests are justifiable and that decisions are clearly documented.

This Guidance document should be read in conjunction with the accompanying notice and the relevant sections of other applicable guidelines and applicable regulations.

This Guidance document is dynamic in nature, and is offered without prejudice to future measures, which Health Canada and the CFIA might take in this area. Persons using the information in this document do so at their own risk and responsibility and are liable for their use of and any reliance on the information contained in it and any loss or damage resulting there from.

Table of contents

• 1. Introduction
  • 1.1 Background
  • 1.2 Definitions
  • 1.3 Context
  • 1.4 Purpose and objectives
• 2. Scope and application
  • 2.1 Scope
  • 2.2 Application
• 3. Guiding principles
• 4. Classification criteria
  • 4.1 Route of administration
  • 4.2 Mode of administration
    • 4.2.1 Final product form
    • 4.2.2 Forceable administration
  • 4.3 Known medicinal ingredients
  • 4.4 Representation/Intended purpose
    • 4.4.1 Therapeutic indications (claims)/purposes
    • 4.4.2 Nutritional indications (claims)/purposes
  • 4.5 Composition
    • 4.5.1 Type of ingredients
    • 4.5.2 Concentration (or level) of ingredients
  • 4.6 Directions for use
    • 4.6.1 Dosage recommendations/Feeding rates
    • 4.6.2 Duration of treatment/feeding & timing of administration
  • 4.7 Mode of action
    • 4.7.1 Therapeutic modes of action
    • 4.7.2 Nutritional modes of action
• 5. Classification decision process
• 6. Implementation

List of appendices

• Appendix A - Nutritional disorders
• Appendix B - Drug/Feed classification flowchart
• Appendix C - List of known medicinal ingredients
• Appendix D - Stress-Related Indications (or Claims)
• Appendix E-1 - Mycotoxin Detoxification Agents (MDAs)

Introduction

1.1 Background

In Canada, products consumed by livestock species are largely regulated as either veterinary drugs or livestock feeds.

Veterinary drugs (henceforth referred to as drugs) are regulated under the Food and Drugs Act and Regulations by Health Canada. Within Health Canada, the Veterinary Drugs Directorate (VDD) has the mandate to evaluate and monitor the safety, quality and effectiveness, to set standards and to promote the prudent use of veterinary drugs, including veterinary natural health products, administered to food-producing and companion animals. The VDD's classification of a product is guided by the requirements of the Food and Drugs Act and Regulations.

Livestock feeds (henceforth referred to as feeds) are regulated under the Feeds Act and Regulations, which are administered by the Canadian Food Inspection Agency (CFIA). The CFIA verifies that livestock feeds manufactured and sold in Canada or imported are safe, effective and are labelled appropriately. Effective feeds contribute to the production and maintenance of healthy livestock.

1.2 Definitions

Pursuant to the Food and Drugs Act, a "drug" includes any substance or mixture of substances manufactured, sold or represented for use in

1. the diagnosis, treatment, mitigation or prevention of a disease, disorder, abnormal physiological state, or its symptoms in human beings or animals,
2. restoring, correcting or modifying organic functions in human beings or animals, or
3. disinfection in premises in which food is manufactured, prepared or kept.

Pursuant to the Feeds Act, a "feed" is defined as any substance or mixture of substances containing amino acids, antioxidants, carbohydrates, condiments, enzymes, fats, minerals, non-protein nitrogen products, proteins or vitamins, or pelletizing, colouring, foaming or flavouring agents and any other substance manufactured, sold or represented for use:

1. for consumption by livestock;
2. for providing the nutritional requirements of livestock, or;
3. for the purpose of preventing or correcting nutritional disorders of livestock,

or any substance for use in any such substance or mixture of substances.
A definition and interpretation of a nutritional disorder can be found in Appendix A.

1.3 Context

The overlap of the definitions for these two types of products creates a challenge whereby nutritional and non-nutritional products may be classified as either a drug and a feed, or both. In the past, difficulties associated with the interpretation of the drug and feed definitions have resulted in significant confusion, which led to inefficiencies regarding product evaluation and approval, as well as compliance and enforcement activities. Therefore, there is a need for a clear and transparent classification process for some products intended for use in livestock species.

1.4 Purpose and objectives

The purpose of this guidance document is to present guidelines and criteria for classification in order to clarify the differences between drugs and feeds, and to assist in determining the appropriate regulatory oversight for a product destined for use in livestock species. The pursued objectives are:

1. to improve the transparency of the classification process, to increase the consistency in decisions by regulators, and make these more predictable to stakeholders;
2. to resolve industry confusion and to provide better guidance to manufacturers of such products regarding the appropriate regulatory department, submissions and processes for a product approval.

2. Scope and application

2.1 Scope

The classification approach presented in this document applies to a broad range of products, intended for oral consumption only and for livestock species (dairy and beef cattle, sheep, fish, goats, chickens, turkeys, ducks, geese, rabbits, horses and swine) only, and in most types of animal production (for ex., dairy cattle vs. beef cattle, broilers chickens vs. laying hens). In some situations, products may neither fit a drug nor a feed classification. Such products may be classified (and therefore regulated) as veterinary biologics, veterinary medical devices, disinfectants, pest control products or consumer products. Please note that these types of products are beyond the scope of this guidance and will not be further discussed in this document. Medicated feeds have a clear regulatory definition and are also excluded from the scope of the classification guidance.

2.2 Application

This guidance document is applicable to products (drugs and feeds) that are subject to the pre-market evaluation process (new) and to the existing products currently sold on the Canadian market (authorized for sale). The present document is intended to be used in conjunction with other regulatory tools from Health Canada and CFIA, such as feed schedules, policies, guidelines, regulations, etc.

3. Guiding principles

For a product classification to be consistent with both regulatory mandates, the following general principles will be applied:

1. The primary consideration will be the respect of the definitions of a drug in the Food and Drugs Act and of a feed in the Feeds Act. Guidance will be consistent with the objectives of Health Canada and CFIA and their respective regulatory frameworks, including public health and safety.
2. Classification decisions from other international veterinary regulatory authorities will be considered during the classification process.
3. The potential risk to health from an ingredient or a product is generally not a factor for classification - it is taken into consideration during assessment of the product's safety (AFTER the product has been classified). The regulatory frameworks under the drug and feed legislations provide a tier of controls to mitigate the risks posed by a product. If these risks are considered unacceptable, itwill result in the product not being permitted for sale, regardless of its classification.
4. The determination of a drug or feed classification can result from the consideration of only one of the most pertinent classification criterion listed below, but generally requires the consideration of multiple criteria taken together as a whole.
5. Depending on the product, some criteria may not be given equal weight in support of a classification decision.
6. Some products may be considered both nutritional and therapeutic, based on differences in ingredients concentrations, dosage recommendations/inclusion rates or other factors.

Based on a complete assessment of each of the criteria identified below, the differences between drugs and feeds can be identified to facilitate a regulatory classification. Please see the document Drug/Feed classification flowchart (shown in appendix B) for a step-by-step approach to the classification process.

4. Classification criteria

4.1 Route of administration

The fact that a substance or a product is administered in feed or in water does not have a significant impact on the regulatory classification of a product.

4.2 Mode of administration

4.2.1 Final product form

The product form refers to the final form in which a substance or product is available and ready for use/administration, without requiring any further manufacturing. Common product forms for therapeutic products (or "dosage" forms) include tablets, capsules, boluses, aerosols or inhalers, creams, lotions, solutions or suspensions and implants.

The form of a product is usually dependent on the route of administration of the substance in question. Most products in dosage form are considered drugs, with some exceptions, depending on other criteria (for ex., purpose, label). Products in forms that can be consumed in a voluntary manner, such as mash, liquid, pellets, flakes, free choice blocks, etc., are typically (but not exclusively) classified as feeds.

4.2.2 Forceable administration

Generally, products for forceable administration (administered orally but via gavages or drenches) are considered drugs. However, some pastes, pumps and non-injectable syringes that are:

1. labelled for inclusion into feeds, and
2. for which no drug claim is made,

are regulated as feeds under the Feeds Act and Regulations. All products must indicate physical form in their product name (for ex., paste) in order to be considered feeds.

All other products for forceable administration will continue to be regulated as drugs.

4.3 Known medicinal ingredients

Some ingredients are inherently medicinal or therapeutic in nature, either due to their characteristics, their function (activity) and effect(s) on the organism or their purpose in the formulation. For example, some substances like penicillin, neomycin, or plant extracts like digitalin or digoxin have an intrinsic therapeutic function or activity. This knowledge is usually derived from scientific literature or reference textbooks. In the case of a multiple-ingredient product, if one or more ingredients in its composition have a therapeutic nature or effect, the product would be considered a drug. Also, some herbal ingredients have a generally recognized therapeutic use and no recorded nutritional use. These types of herbal ingredients are considered medicinal ingredients and classified as drugs.

To help identify ingredients currently considered as medicinal (therapeutic), please refer to Appendix C for a definition and an alphabetical listing of known medicinal ingredients.

4.4 Representation/Intended purpose

Key considerations for the classification of a product are its representation (1) and intended purpose (2):

1. The representation associated with a product include indications for use (they may be explicit or implied), health claims presented as a word, sentence, a picture, a symbol, a paragraph or an implication on product labels, package inserts or advertisements (including information available on the Internet), as well as its intended purpose and history of use.
2. The intended purpose of a product is the desired effect to be achieved by the administration of this product to a particular animal species during a particular situation, or under specific conditions (for ex., health or disease states, nutritional needs). The activity or properties of the ingredient(s) present in a product are also considered to provide information on the product's intended (desired) effect.

Together, these product characteristics are used to create a clear picture of what the product is and does. While the "representation for use" criterion would not be considered the only basis for a classification decision, it may be taken into account and influence the final decision because of its impact on the purpose of the product. Therefore, an indication/claim present on a product label or in the advertising material is an important but not determining factor to be considered for product classification.

However, indications (or claims) present on a product, whether they are supportable or not, will be determinants for the submission of an application to the appropriate regulatory body. For the classification of products in the "grey zone" between drugs and feeds, applications should be submitted to VDD as a single-window contact for classification.

Notes on advertising:
In classifying products, VDD and CFIA's Animal Feed Division (AFD) may also look to how the product is advertised or promoted. Although web sites alone are not extensions of the label of a product, claims made in the media, including those made on web sites of various stakeholders or social media, may be considered evidence of the intended purpose of the product for classification purposes.

4.4.1 Therapeutic indications (claims)/purposes

Therapeutic claims, indications or purposes refer to the treatment of a disease, disorder or abnormal physical state; or treatment, mitigation of its symptoms; or the modification of an organic function (such as digestion). Therapeutic claims can only be made for products which have a therapeutic purpose or intent of use (drugs), and are therefore not suitable for feeds. Examples of therapeutic (or drug) claims are:

• Treatment claims (treatment of a disease (acetonemia), a condition (intoxication) or abnormal state (wounds, oedema) or its symptoms (diarrhea);
• Control claims (control intestinal parasites, control breeding);
• Prevention claims (prevent mastitis, prevent acetonemia, prevent bloat, prevent coccidiosis), excluding prevention of nutritional deficiency claims;
• Mitigation claims (reduce severity of pneumonia, relief pain associated with colic, relief of inflammation, decrease incidence of laminitis, reduction of early mortality);
• Animal Performance claims (production claims) not supported by a nutritional purpose or mode of action (stimulate egg production, increase litter size).

Note: This list of acceptable indications for drugs is not exhaustive and others indications or claims not acceptable for feeds would require further assessment for classification.

4.4.2 Nutritional indications (claims)/purposes

Feeds are not intended to have any therapeutic purpose or activity. Products with such purposes are not considered feeds but are considered drugs. Feed products are typically fed for a reasonable amount of time as part of a balanced feeding program with the intent of meeting the nutritional requirements necessary for maintenance, growth and production of livestock. They can also include non-nutritive products such as flavours, pellet binders, preservatives, anti-caking agents and other products that facilitate the manufacture, storage or palatability of feeds. Feeds are also known to be vehicles (carriers) for delivery of therapeutic products such as medicated feeds.

Nutritional indications or purposes refer to the presence of one or more nutrient(s) or nutritive substance(s) which are scientifically recognized for providing the nutritional requirements essential for supporting growth, maintenance and production in livestock species. An intended purpose that states suggests or implies that the consumption of a specific nutrient or nutritive substance significantly reduces the incidence or prevents the development of a nutritional disease; disorder or deficiency in a healthy animal may also be acceptable in this category of claims. Examples of nutritional claims that would be acceptable for feeds include:

• Nutritional disorder prevention claims excluding disease prevention (prevention of "white muscle disease" in cattle due to selenium deficiency; prevention of anemia due to iron deficiency in neonatal piglets, prevention of scoliosis due to vitamin C deficiency in salmonid fish);
  More information on nutritional disorders can be found in Appendix A.
• Animal performance (Production) claims within a nutritional context (increased milk production from feeding a by-pass; amino acid (compared to unprotected source of the same nutrient));
• Increased nutrient bioavailability (organic complex minerals claiming increased bio- availability compared to a certain inorganic source; enzymes such as phytases to increase available phosphorus).

Feeds can also be non-nutritive for the following purposes or claims:

• Nutrient preservation (for ex., forage additives, mould inhibitors, feed antioxidants) not supported by a therapeutic purpose or mode of action (please see section 4.7 on Mode of Action);
• Facilitating agents intended to aid or improve the manufacturing or handling properties of a feed (for ex., pelleting aid, anti-caking agents, carriers, etc.) not supported by a therapeutic purpose or mode of action;
• Colouring agents to colour the feed or tissues/eggs of livestock;
• Flavouring agents to flavour feeds.

Note: Products making nutritional claims on their label will require registration with CFIA prior to import, manufacture and sale in Canada. These types of claims would be permitted for feeds provided that they are supported by adequate scientific evidence that has been assessed and approved by the CFIA's Animal Feed Division (AFD).

4.5 Composition

Although the composition of a product alone does not necessarily determine its classification, the presence of an ingredient, or its level, may aid in determining the correct regulatory classification of that product.

4.5.1 Type of ingredients

The components of a product or its ingredients are assessed to determine the activity or purpose of that product. The nature of each ingredient, its intrinsic characteristics, its physical and chemical properties, the degree of modification (for ex., compound, extract, isolate) and it associated function(s) and role(s) in the product are investigated in detail to provide evidence to support the intended use of a product.

4.5.2 Concentration (or level) of ingredients

The concentration, strength or level of ingredients may be useful in determining its particular role in the formulation and the intent (or purpose) of the ingredient in the product as a whole. An ingredient may have a particular function until it reaches a certain threshold or concentration, at which point it has a pharmacological or therapeutic effect (for ex., propylene glycol 1% or less = inactive ingredient vs. propylene glycol 50% or 100% = active ingredient).

Also, a nutritional ingredient such as a vitamin or a mineral can have a therapeutic effect at a higher amount, based on the concentration in the product and dosage recommendations (for ex., calcium, iron, copper, zinc, vitamin A, vitamin C, some plants and plant oils, etc.).

4.6 Directions for use

4.6.1 Dosage recommendations/Feeding rates

The recommended dosage or rate of administration of a product may assist in identifying the therapeutic or nutritional purpose of that product. For example, a very specific dosage regimen may suggest a therapeutic purpose or intended effect for a product.

The inclusion rates or dosage recommendations can sometimes be considered for classification of products as drugs, particularly for vitamin, mineral or electrolyte products. For feed products, the feeding rate is used to determine if the final amount of an ingredient or nutrient received by a particular species is within or higher than regulatory standards (for ex., supplementation levels recommended by NRC, Table 4 maximums, maximum limits prescribed in Schedule IV and V of the Feeds Regulations, etc.).

4.6.2 Duration of treatment/feeding & timing of administration

The duration of treatment and timing of administration criteria do not automatically lead to a drug or feed classification.

These specifics of directions for use are usually not a useful or relevant consideration for the classification of a product as a drug. They are quite varied for drug products since they are closely associated with the animal species and the disease (or condition) for which the drugs are indicated.

In general, products considered as feeds are part of a balanced feeding program and have to be fed for a reasonable period of time, on a continuous basis. The duration of mineral or vitamin supplementation may vary according to specific physiological periods in the production life of animals. For example, a nutritional product to be fed to dairy cattle in lactation or during gestation, or a mineral product fed during the first days of life for piglets, would be consistent with a feed supplementation regime.

4.7 Mode of action

In biological terms, a mode of action (MoA) refers to the mechanism or the manner in which an action, effect or result is obtained in an organism. The MoA and its effect are often related to the chemical structure of an ingredient or substance. A substance usually exhibits its action through an interaction between that substance and a cellular constituent, usually referred as a receptor, which results in a direct response, or which blocks the response to another agent. There are many specific receptor site(s) or enzyme(s) in a body that can trigger a biological response to a substance.

4.7.1 Therapeutic modes of action

A therapeutic mode of action is the specific biochemical interaction through which an ingredient (or combination of ingredients) produces a pharmacological effect. For example, acetyl salicylic acid (chemical substance) produces an irreversible inhibition of the enzyme cyclooxygenase (MoA), which suppresses the production of prostaglandins and thromboxanes (physiological effect), thereby reducing pain and inflammation (therapeutic effect).

Similarly to a pharmacological action, immunological and metabolic actions are also considered to be biochemical interactions leading to a particular biological response. An immunological action is an action in or on the body by stimulation and/ or mobilisation of cells and/or products from the immune system. A metabolic action is an action that involves an alteration, including stopping, starting or changing the speed of the normal chemical processes participating in, and available for, normal body functions (for ex., a partitioning agent for growth promotion).

When an ingredient or a product has an action that restores, changes or affects the physiological function(s) of an animal beyond the generally recognized physiological effects of nutrition, this action falls within the definition of a drug as per the Food and Drugs Act and is considered to be therapeutic.

Modes of action consistent with drugs:

• Indirect mechanism to stimulate appetite (stimulation of the CNS);
• Mode of action in both feed and animals (antifungal substance added at a high concentration in feeds, for prevention of moulds in the feed and mycotoxicosis in cattle);
• Any mode of action inside the animal, not related to the digestive process;
• Specific internal mechanism of action, such as:
  1. modification of cells or cellular functions;
     (for ex., insulin stimulate cells to absorb blood glucose)
  2. modification of a protein, enzyme, amino-acid, or its activity;
  3. modification of an organ or its activity;
     (for ex., decrease size of thyroid or decrease its activity)
  4. modification, elimination or blocking of a metabolic pathway;
• Bio-regulation mechanisms (bio-feedback) which controls expression and/or modification of some biological components;
• Artificial stimulation of the non-specific (innate) immune system:
  1. Recognition phase:
     1. production of an increase number of immunological cells or proteins;
     2. activation of the complement reactions;
  2. Elimination phase:
     1. increased phagocytic activity of immunological cells;
     2. increased cytotoxic activity of immunological cells;
     3. increase in cellular migration and in the inflammatory reaction;

     Excluding the mechanisms resulting in the development of an adaptative or acquired immunity (an immunological response or the modulation of an immune response to an infectious agent) in animals, which are associated with the veterinary biologics (for ex., vaccines and antibody products, including adjuvants).

• Action on the intestinal flora (substance/product not absorbed by the body and acting directly within the intestinal lumen) that may have some prophylactic/therapeutic effect.

Note: This list of acceptable modes of action for drugs is not exhaustive. Other modes of actions would require a description and further assessment for classification.

4.7.2 Nutritional modes of action

A nutritional mode of action could be defined as a process where recognized nutrients (when supplied at required levels), are digested/absorbed by the animal to maintain physiological functions, resulting in minor differences in biological activity and without a significant and lasting change or modification on the cellular, tissue, organic and metabolic reactions of the body. This process usually results in established and recognized physiological rates of growth, maintenance and/or production characteristics for healthy livestock species.

In the context of feeds, a nutrient can be defined as any substance that can be metabolized by an animal to give energy and build or maintain tissue to meet scientifically supported nutrient requirements. There are six types of nutrients: minerals, vitamins, fats, protein, carbohydrates and water.

Modes of action consistent with feeds:

• Action directly in the feed itself, before consumption, to improve or conserve the nutrient content of the feed , to aid or improve in the manufacturing or handling of the feed and to change the colour or smell of feeds (for ex., pellet binders, flow agents, colouring agents, flavouring agents, mould inhibitors, mycotoxin binders);
• Action limited to the normal digestive process of feeds (for ex., absorption of mineral and vitamins through the intestinal mucosa, improve digestibility and bioavailability of nutrients).

Note: This list of acceptable mechanisms of action for feeds is not exhaustive.

The MoA criterion may not always be a definitive one and should be evaluated in conjunction with other criteria such as the physiological particulars of the intended species (for ex., ruminants vs. non-ruminants), intent of use and concentrations of ingredients, before a final classification decision can be reached.

5. Classification decision process

The Veterinary Drug Directorate (VDD) and the Animal Feed Division (AFD) of CFIA encourage sponsors to initiate the classification process of their products by using the present guidance document, flowchart and other appendices. After self-assessing that a product would be classified as a drug, they can contact the VDD for information on submission requirements. The Veterinary Drugs section of Health Canada's website can also be consulted for additional information.

Once a product is determined to be a feed, they can proceed to submit a registration application to the AFD. Information on the registration process is available in the Regulatory Guidance section of CFIA's website.

If classification questions remain or issues arise after the review of this guidance, sponsors should contact VDD, as a single-window access for classification. VDD will collaborate with the AFD for information sharing and discussion to reach a joint classification decision. The applicant will be informed in writing of the final decision concerning the regulatory classification of a product. Drug decisions will be communicated by VDD; feed decisions will be communicated by AFD.

A classification template has been developed to facilitate the organization and presentation by the industry of the necessary information for an accurate product classification. Please contact VDD directly to obtain this template.

Classification requests from industry should include a cover letter, the completed classification template and the related supporting documentation. All classification requests should be submitted in writing (mail, e-mail or fax) to VDD.

Any classification reconsideration request should also be submitted in writing to VDD and be accompanied with a valid scientific rationale, as well as the appropriate supportive documentation. VDD will consult with AFD as needed.

6. Implementation

This guidance document will come into effect as of the online publication date. The publication, coordination and implementation of this guidance document of understanding will be the joint responsibility of Health Canada's VDD and the CFIA's AFD. For questions or additional information on the content of this document, please contact VDD.

Appendix A

Nutritional disorders

1. Definitions:

• Disease: An impairment of the normal state of the living animal or plant body or one of its parts that interrupts or modifies the performance of the vital functions, which is typically manifested by distinguishing signs and symptoms, and is a response to environmental factors (as malnutrition, industrial hazards, or climate), to specific infective agents (as worms, bacteria, toxins, or viruses), to inherent defects of the organism (as genetic anomalies), or to combinations of these factors.
  (Reference: Merriam -Webster Medical Dictionary)

  In short, a disease refers to damage to an organ, part, structure, or system of the body such that it does not function properly or a state of health leading to such dysfunction.
  Examples: heart disease, diabetes, bile duct obstruction.

• Nutrient: As defined under section 4.7.2 "Nutritional modes of action" (second paragraph), a nutrient can be defined as any substance that can be metabolized by an animal to give energy and build or maintain tissue to meet scientifically recognized nutrient requirements. There are six types of nutrients: minerals, vitamins, fats, protein, carbohydrates and water.
• Nutritional disorder: Any disorder in animals that is directly or indirectly caused by a lack of nutrients or a nutritional imbalance in the diet.

  Metabolic disorders and multifactorial disorders in which nutrition plays an important role are not considered to be nutritional disorders. Examples of such conditions are: post-parturient hypocalcemia (milk fever); acetonemia (ketosis) or pregnancy toxemia; metabolic acidosis; laminitis; abomasal displacement; enterotoxemia; urolithiasis (urinary calculi).

• Tonic (or conditioner): As defined under Subsection 2. (1) Interpretation of the Feeds Regulations 1983, a tonic or conditioner means a mineral feed formulated and represented for the correction of a specified nutrient deficiency or to aid recovery from a specified nutrient deficiency and is for use only while the condition persists (for ex., single-ingredient product of magnesium, or zinc).

2. Criteria:

Criteria for a nutritional disorder:

1. Presence of deficiency, excess or imbalance of a specific nutrient in the diet;
2. Cause/effect relationship between clinical signs of disorder and absence of nutrient in the diet;
3. Diet supplementation prevents and/or resolves the condition

All criteria need to be met for a condition to be considered a nutritional disorder.

If one of the above drug criteria is met, the ingredient or product would be excluded from a feed classification and considered a drug.

Any treatment claim or therapeutic indication associated with these nutritional conditions (diseases) would result in the product being classified as a drug. Prevention/correction claims would be acceptable for feeds under the following situations:

1. Prevention:
   1. when it is intended to meet nutritional requirements, and
   2. when it is intended to prevent a nutritional disorder caused by a deficiency in one specific nutrient, by a modification of the diet.
2. Correction: when referring to the correction of a specific nutritional disorder caused by a deficiency in one specific nutrient, by modification of the diet.
3. Approved nutritional sources are used for nutrient supplementation (for ex., Schedule IV of the Feeds Regulations)

Note: Products making such claims on their label will require registration with CFIA prior to import, manufacture and sale in Canada.

Appendix B

Appendix C

Known medicinal ingredients

1. Introduction

A known medicinal ingredient is a substance, part of a substance or a combination of substances associated with a therapeutic (medicinal) property or pharmacological effect. Based on a large number of classification requests, VDD and AFD have established a list of substances which have been classified as medicinal ingredients. These classifications were made based on the scientific knowledge current at the time of the request and related to the indications proposed by the sponsor. However, some medicinal ingredients may also have a non-medicinal purpose, depending of the concentration (level) or other factors. For your information, the list contains these "exceptions", which are ingredients listed on the Feeds Schedules IV and V in the Feed Regulations and used in feeds for non-medicinal purposes.

Important notes:

1. The following list has been developed only for the purpose of this document, in order to facilitate product classification. It should not be considered as an exhaustive and complete list. However, it is our commitment to update/revise it on a regular basis.
2. Classifications associated with proprietary information have not been included in this list.
3. If a substance is not present in the list below, and you wish to ascertain the classification of this substance, the classification template can be submitted to VDD for classification purposes. For any questions, comments, additional guidance or to obtain the template, please contact VDD.

Appendix D

Stress-Related Indications (or Claims)

1. Introduction

Historically, almost all indications or claims containing the term “stress” were associated with a therapeutic purpose, hence a drug classification. The purposes of this appendix are to clarify in more detail for stakeholders:

1. the acceptability of the use of the word “stress” in product indications; and
2. which type of stress-related indications are considered therapeutic (drug-related), as well as which ones are considered non-therapeutic and acceptable for livestock feeds.

2. Definition

For the purpose of this document “stress” is defined as “the sum of the biological reactions to any adverse stimulus physical, mental, or emotional, internal or external, that tends to disturb the homeostasis of an organism. Should these reactions be inappropriate, they may lead to disease states. The term is also used to refer to the stimuli that elicit the reactions, e.g., heat, nutritional, lactational, confinement, transportation.”
(according to Baillère’s Comprehensive Veterinary Dictionary)

3. a) Criteria for acceptability of stress-related indications

• Clarity:
  The term “stress” is too general in describing the condition of an animal. It is recommended that product labelling and advertising avoid the vague, imprecise and confusing use of the term “stress”.
• Specificity:
  In cases where the word stress is used, it must be accompanied with concrete and measurable qualifiers. To specify the context, the cause(s) of stress, the impact (consequences), the purpose/intent of use of the product, or the timing of administration, needs to be added in the indication.

Examples of unacceptable indications (claims) are given in table 3.1 at the end of this document.

3. b) Criteria for classification of stress-related indications

• Stress-related indications (claims) will be classified as therapeutic or non-therapeutic independently of the timing of the stress event/change or of the product administration.
• An indication (claim) related to stress is considered to be therapeutic if it refers to:
  1. a product preventing or treating major/severe consequences (including clinical signs and diseases) of a stressful event or change; and/or
  2. a product directly affecting the physiological function or structure of organs in animals in a stressful situation.

In other words, claims which refer to the reduction of clinical signs or altered organ structure or function, when triggered by a stressful event, are only appropriate for veterinary drugs.

• An indication (claim) related to stress is considered non-therapeutic if it refers to:
  1. a product providing nutrients or supporting a nutritional intent; and/or
  2. a product supporting animal performance (i.e., production claims) in presence of stressful events or procedures associated with normal animal husbandry practices (e.g., vaccination, castration, dehorning, tail clipping, etc.).

Examples of therapeutic and non-therapeutic indications are also given in the table 3.1 below. Please note that this table is for illustrative purposes only and should not be considered as an exhaustive & complete list.

4. Other Considerations

Please note that, as with all classifications, the criteria and process described in the Drug/Feed Classification flowchart (especially those indicated in the circle) will be followed for the classification of a product intended for use in periods of stress.

Appendix E-1

Mycotoxin Detoxification Agents (MDAs)

1. Background

Mycotoxins are toxic compounds produced by different types of fungus (mainly Aspergillus, Penicillium and Fusarium genera). Under favourable environmental conditions, particularly those linked to temperature and moisture, these fungi may proliferate in livestock feeds such as cereal grains, and produce mycotoxins. Attempts to reduce mycotoxin contamination have prompted the utilization of various techniques and products including heat-treatment, physical separation, soaking, de-hulling, or cleaning of seeds. The use of Mycotoxin Detoxification Agents (MDAs) is one technique that is discussed in this annex. The general purpose of MDAs is to ensure feed safety, to prevent harmful residues from entering the food chain, and to prevent animal disease. Due to product classification issues arising from the uses of MDAs, the classification criteria previously used are now being reconsidered and clarified as follows.

2. Definition

Mycotoxin Detoxifying Agents (MDAs): MDAs are substances or mixtures of substances incorporated into a feed matrix to mitigate the toxicity of known mycotoxins by reducing the animal’s exposure to mycotoxins. This may be done by reducing their reactivity through direct binding, decreasing their bioavailability, reducing their intestinal absorption, or promoting their excretion.

3. Relevant classification criteria

3. a) Mode of action

MDAs may be regulated as a veterinary drug or a livestock feed depending on the mode of action as demonstrated or claimed by the product proponent.

• If the mode of action involves physiological functions in the animal system (such as binding to the gastrointestinal (GI) mucosa, stimulating the immune response, eliciting an endogenous enzymatic response, absorption into the systemic circulation, metabolic transformation), then the MDA may be classified as a veterinary drug.
  
  As an example, digestives enzymes can inactivate some mycotoxins. Another example would be a combination product including a binding substance and an ingredient that helps hepatic detoxification processes.
• If the mode of action occurs in the feed matrix prior to the ingestion of the treated feed by the animal (e.g., binding to the mycotoxin or inactivation), then the product may be classified as a livestock feed. An MDA may also be considered a feed if the mode of action occurs after solubilisation within the GI tract so long as the effects do not depend on systemic absorption.
  
  As an example, aluminosilicates bind some mycotoxins, thus preventing their absorption across the digestive tract. Another example is the enzymatic degradation or biotransformation of mycotoxins by exogenous enzymes to reduce potential toxicity.

Products with a dual mode of action, or having other modes of action should be submitted to VDD for further assessment for classification.

3. b) Mycotoxin-related indications

• Indications related to the prevention of disease in animals or indications related to the treatment of clinical signs of mycotoxicosis (or associated diseases) would be considered therapeutic in nature. Products presenting such indications would be classified as veterinary drugs. Examples of acceptable indications for veterinary drugs are given in the table below:

• Indications related to reducing the contamination of feeds by acceptable modes of action in feed may be considered as non-therapeutic indications. Products presenting such indications may be acceptable for classification as livestock feeds. Examples of acceptable indications for livestock feeds are given in the table below:

4. Other considerations

• Please note that MDAs will not be permitted for use in feeds that do not comply with Canadian standards for mycotoxins.
• As with all classifications, the criteria and process described in the Drug/Feed Classification flowchart will be followed.